As Director, Scientific Affairs, Dr. Aernout van Haarst plays a key role in leveraging Celerion’s scientific and drug development expertise to support drug development programs of Celerion’s clients. He is a member of Celerion’s respiratory and vaccine research teams and is the scientific liaison to various external experts in the fields of pulmonology and vaccine development.
Arkadiusz K. Kuczaj earned his PhD (2006) in the field of Applied Mathematics from the University of Twente, the Netherlands. As Manager of Aerosol Research and Dosimetry, he is currently leading aerosol delivery and characterization, in vitro exposure, and in vivo inhalation research in the Biomedical Research Department (BMRD) at Philip Morris International R&D (PMI R&D) in Neuchatel, Switzerland.
He published and co-authored more than 30 technical manuscripts in the field of life-science, aerosol research, computational physics and fluid dynamics.
Dino Farina founded Proveris in 1995 to help customers develop and deliver quality orally inhaled and nasal drug products (OINDPs). Since that time, Dino has applied his business experience and technical expertise in optical measurements of fluid flow, experiment design, analysis, and pharmaceutical regulatory science to provide customers innovative products and laboratory services that aid in the development, submission and release of OINDPs.
Dr. Fakhrul Ahsan is a University Distinguished Professor in the Department of Pharmaceutical Sciences at the Texas Tech University Health Sciences Center (TTUHSC) School of Pharmacy in Amarillo, Texas. A pharmacist by training, he earned his pharmacy degree from the University of Dhaka in Bangladesh.
Dr. Francesca Buttini is Associate Professor at the Food and Drug Department, University of Parma (IT) where she is leading the unit dedicated to design of pharmaceutical products for inhalation.
She has published more than 60 research papers. Finally, Francesca is a founder of PlumeStars, an innovative SME dedicated to development of orphan drug products to treat lung disease.
Jeffry Weers is currently the Chief Technical Officer at Respira Therapeutics, Inc. He holds a B.S. degree in Chemistry from the University of Puget Sound (1980), and a Ph.D. in Physical Chemistry from the University of California, Davis (1985).
Previously, Jeff was the Chief Scientific Officer for Respiratory at Novartis Pharmaceuticals Corporation (2009-2017). Prior to joining Novartis, Jeff spent roughly a decade (1999-2008) with Nektar Therapeutics (formerly Inhale Therapeutic Systems), where he held various positions within the Research and Development organization.
Dr Jörg Schiewe is the Head of Global CMC Experts at Boehringer Ingelheim Pharma GmbH & Co. KG, Germany.
He studied chemistry at the Martin-Luther-University in Halle, Germany and earned his PhD in the field of physical chemistry in 1994. The Alexander von Humboldt foundation awarded Dr. Schiewe a Feodor-Lynen-Fellowship to perform post-doctoral work with Prof. Alan Bond at Monash University in Melbourne, Australia (1995-1997).
Justin Kalafat is responsible for collaborating with pharmaceutical industry for capsule business. Prior to joining ACG in 2014, his background includes degrees in chemistry and roles within the generic pharmaceutical industry in quality control and procurement.
His experiences enable key strategies to be developed with customers, R&D focused institutions and universities on the technical aspects of capsules as a dosage form solution.
Marco Laackmann has an Engineering degree in Chemical Engineering applied Biotechnology from University of Applied Science Emden in Germany and a MBA from Bradford School of Management in UK.
His background includes 15 years of experience in various areas of Dry Powder Inhaler covering aspects of device development, manufacturing and quality control of medical devices as well as powder dosing technologies and process development.
Mark is responsible for the Product & Health Solutions within Digital Health at TEVA Pharmaceuticals. Over ten years with TEVA and prior to that sixteen with AstraZeneca. Mark has held various positions including R&D Project Leader, VP Sales & Marketing, Strategic Planning & Business Development, and Global Brand Lead.
Martin Wing-King is the Director of Project Management at Quotient Sciences’ Reading, UK facility. Martin began his career in Analytical Development at Johnson Matthey, and over the course of 8 ½ years transitioned from the lab into a sales role within the company.
Martin is currently part of a team that assesses new business opportunities coming into Quotient Sciences and is considered to be one of the inhalation development subject matter experts. Martin obtained his degree from Brunel University, London in Chemistry with management (2000).
Dr. Masahiro Sakagami is a Professor in the Department of Pharmaceutics at the Virginia Commonwealth University (VCU) School of Pharmacy in Richmond, Virginia, USA. He received B.S. and M.S. in Chemical Engineering at Waseda University in Japan (1989 and 1991, respectively); and a Ph.D. in Pharmaceutical Sciences at VCU (2000). In 1991-1996, he was an inhalation drug delivery scientist at Teijin Ltd., a pharmaceutical industry in Japan.
Michael Castagna is Chief Executive Officer and serves on the Board of Directors for MannKind Corporation. Dr. Castagna has over 20 years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries.
Dr. Castagna serves on the board of directors of Pet Partners headquartered in Bellevue, Washington. Dr. Castagna received his Bachelors of Science – Pharmacy degree from Philadelphia College of Pharmacy, his Doctor of Pharmacy from Massachusetts College of Pharmacy, and his MBA from the Wharton School of Business at the University of Pennsylvania.
Nathalie Heuzé-Vourc'h is a senior research scientist at The National Insitute of Biomedical Sciences in France and is leading a multidisciplinary team dedicated to "Aerosoltherapy and Biotherapeutics for Respiratory Diseases".
She has published more than 60 articles so far and is interested in the multifacets of biotherapeutics inhalation. She often serves as a scientific expert for the European Commission and for biotechs. She is a member of the Scientific committee of the french Health Technologies Institute.
Peter Robbins is Professor of Physiology at the University of Oxford. He has a strong reputation for developing innovative technologies to address previously intractable questions in human physiology, particularly relating to respiratory and cardiovascular function. His interests include hypoxia biology and iron homeostasis. In these areas, he has had a long-term collaboration with Professor Sir Peter Ratcliffe, the 2019 Nobel Laureate in Physiology or Medicine.
Simon Moore joined Envigo in 1999 as an inhalation study analyst and was promoted quickly within the Aerosol Technology and Analysis section. When the section expanded and divided in 2003 into inhalation chemistry and aerosol technology, Simon was promoted to the role of Head of Aerosol Technology with managerial responsibility for the aerosol technologists. In 2009, he took managerial responsibility for the inhalation engineering services group. In 2016, he was promoted to his current title.
Prof. Dr. Sven Stegemann is professor of patient centric drug design and manufacturing at the Graz University of Technology, Austria. Over the course of his 27-year career in the pharmaceutical industry, he has worked as an advisor to major pharmaceutical companies on ways to improve the design, development and manufacture of pharmaceutical products so they better address the individual needs of patients.
Tonya Winders. MBA is currently the President and Chief Executive Officer of Allergy & Asthma Network, the leading patient advocacy organization dedicated to ending the needless death and suffering due to asthma, allergies and related conditions.
Tonya has over 17 years experience in leadership roles within the allergy and asthma industry. From sales and marketing leadership to managed markets access, she has worked tirelessly to ensure patients have access to effective diagnostic and treatment tools.
Dr. Wayland Rushing has 20 years of CMC analytical testing experience, including over 15 years of experience in testing of inhalation drug products.
As the Director of Scientific Affairs he is responsible for designing and implementing CMC testing programs for Eurofins clients, including programs for pMDI’s, DPI’s, Nebulizers, pre-filled syringes along with a variety of other drug delivery and container/closure systems.
He earned his bachelor’s degree from Westminster College and his Ph.D. in Chemistry from the University of Missouri.